Melanomas prevent endothelial cell death under restrictive culture conditions by signaling through AKT and p38 MAPK/ ERK-1/2 cascades

References

• Eggermont AM, Spatz A, Robert C. Cutaneous melanoma. Lancet 2014; 383:816-27; PMID:24054424; http://dx.doi.org/10.1016/S0140-6736(13)60802-8
   PubMed Web of Science ®Google Scholar
• Cummins DL, Cummins JM, Pantle H, Silverman MA, Leonard AL, Chanmugam A. Cutaneous malignant melanoma. Mayo Clinic proceedings 2006; 81:500-7; PMID:16610570; http://dx.doi.org/10.4065/81.4.500
   PubMed Web of Science ®Google Scholar
• Hamid O, Boasberg PD, Rosenthal K, O'Day SJ. Systemic treatment of metastatic melanoma: new approaches. J Surg Oncol 2011; 104:425-9; PMID:21858838; http://dx.doi.org/10.1002/jso.22034
   PubMed Web of Science ®Google Scholar
• Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27:6199-206; PMID:19917835; http://dx.doi.org/10.1200/JCO.2009.23.4799
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob J-J, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A et al. Melanoma. Nat Rev Dis Primers. 2015; 1:15003; PMID:27188223; http://dx.doi.org/10.1038/nrdp.2015.3
   Google Scholar
• Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-16; PMID:21639808; http://dx.doi.org/10.1056/NEJMoa1103782
   PubMed Web of Science ®Google Scholar
• Robert C, Karaszewska B, Schachter J, Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R, Grange F, Mortier L et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372:30-9; PMID:25399551; http://dx.doi.org/10.1056/NEJMoa1412690
   PubMed Web of Science ®Google Scholar
• Carvajal RD, Antonescu CR, Wolchok JD, Chapman PB, Roman RA, Teitcher J, Panageas KS, Busam KJ, Chmielowski B, Lutzky J et al. KIT as a therapeutic target in metastatic melanoma. JAMA 2011; 305:2327-34; PMID:21642685; http://dx.doi.org/10.1001/jama.2011.746
   PubMed Web of Science ®Google Scholar
• Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-23; PMID:20525992; http://dx.doi.org/10.1056/NEJMoa1003466
   PubMed Web of Science ®Google Scholar
• Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372:320-30; PMID:25399552; http://dx.doi.org/10.1056/NEJMoa1412082
   PubMed Web of Science ®Google Scholar
• Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M et al. Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 2015; 372:2521-32; PMID:25891173; http://dx.doi.org/10.1056/NEJMoa1503093
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med 2015; 373:23-34; PMID:26027431; http://dx.doi.org/10.1056/NEJMoa1504030
   PubMed Web of Science ®Google Scholar
• Basu B, Biswas S, Wrigley J, Sirohi B, Corrie P. Angiogenesis in cutaneous malignant melanoma and potential therapeutic strategies. Expert Rev Anticancer Ther 2009; 9:1583-98; PMID:19895243; http://dx.doi.org/10.1586/era.09.135
   PubMed Web of Science ®Google Scholar
• Mahabeleshwar GH, Byzova TV. Angiogenesis in melanoma. Semin Oncol 2007; 34:555-65; PMID:18083379; http://dx.doi.org/10.1053/j.seminoncol.2007.09.009
   PubMed Web of Science ®Google Scholar
• Kashani-Sabet M, Sagebiel RW, Ferreira CM, Nosrati M, Miller JR, 3rd. Tumor vascularity in the prognostic assessment of primary cutaneous melanoma. J Clin Oncol 2002; 20:1826-31; PMID:11919240; http://dx.doi.org/10.1200/JCO.2002.07.082
   PubMed Web of Science ®Google Scholar
• Mehnert JM, McCarthy MM, Jilaveanu L, Flaherty KT, Aziz S, Camp RL, Rimm DL, Kluger HM. Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays. Hum Pathol 2010; 41:375-84; PMID:20004943; http://dx.doi.org/10.1016/j.humpath.2009.08.016
   PubMed Web of Science ®Google Scholar
• Reed JA, McNutt NS, Albino AP. Differential expression of basic fibroblast growth factor (bFGF) in melanocytic lesions demonstrated by in situ hybridization. Implications for tumor progression. Am J Pathol 1994; 144:329-36; PMID:8311116
   PubMed Web of Science ®Google Scholar
• Nurnberg W, Tobias D, Otto F, Henz BM, Schadendorf D. Expression of interleukin-8 detected by in situ hybridization correlates with worse prognosis in primary cutaneous melanoma. J Pathol 1999; 189:546-51; PMID:10629556; http://dx.doi.org/10.1002/(SICI)1096-9896(199912)189:4<546::AID-PATH487>3.0.CO;2-L
   PubMed Web of Science ®Google Scholar
• Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients. Melanoma Res 2006; 16:405-11; PMID:17013089; http://dx.doi.org/10.1097/01.cmr.0000222598.27438.82
   PubMed Web of Science ®Google Scholar
• Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol 2001; 19:577-83; PMID:11208853
   PubMed Web of Science ®Google Scholar
• Mouawad R, Spano JP, Comperat E, Capron F, Khayat D. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer 2009; 45:1407-14; PMID:19157860; http://dx.doi.org/10.1016/j.ejca.2008.12.015
   PubMed Web of Science ®Google Scholar
• Zaki KA, Basu B, Corrie P. The role of angiogenesis inhibitors in the management of melanoma. Curr Top Med Chem 2012; 12:32-49; PMID:22196268; http://dx.doi.org/10.2174/156802612798919240
   PubMed Web of Science ®Google Scholar
• Nikolaou V, Stratigos A, Bafaloukos D, Katsambas A. Antiangiogenic and antiapoptotic treatment in advanced melanoma. Clin Dermatol 2013; 31:257-63; PMID:23608445; http://dx.doi.org/10.1016/j.clindermatol.2012.08.018
   PubMed Web of Science ®Google Scholar
• Emmett MS, Dewing D, Pritchard-Jones RO. Angiogenesis and melanoma - from basic science to clinical trials. Am J Cancer Res 2011; 1:852-68; PMID:22016833
   PubMed Web of Science ®Google Scholar
• Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007; 26:281-90; PMID:17603752; http://dx.doi.org/10.1007/s10555-007-9066-y
   PubMed Web of Science ®Google Scholar
• Rofstad EK, Rasmussen H, Galappathi K, Mathiesen B, Nilsen K, Graff BA. Hypoxia promotes lymph node metastasis in human melanoma xenografts by up-regulating the urokinase-type plasminogen activator receptor. Cancer Res 2002; 62:1847-53; PMID:11912164
   PubMed Web of Science ®Google Scholar
• Rofstad EK, Halsor EF. Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8. Br J Cancer 2002; 86:301-8; PMID:11870523; http://dx.doi.org/10.1038/sj.bjc.6600052
   PubMed Web of Science ®Google Scholar
• Matsushita H, Morishita R, Nata T, Aoki M, Nakagami H, Taniyama Y, Yamamoto K, Higaki J, Yasufumi K, Ogihara T. Hypoxia-induced endothelial apoptosis through nuclear factor-kappaB (NF-kappaB)-mediated bcl-2 suppression: in vivo evidence of the importance of NF-kappaB in endothelial cell regulation. Circ Res 2000; 86:974-81; PMID:10807870; http://dx.doi.org/10.1161/01.RES.86.9.974
   PubMed Web of Science ®Google Scholar
• Westphal JR, van't Hullenaar RG, van der Laak JA, Cornelissen IM, Schalkwijk LJ, van Muijen GN, Wesseling P, de Wilde PC, Ruiter DJ, de Waal RM. Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. Br J Cancer 1997; 76:561-70; PMID:9303353; http://dx.doi.org/10.1038/bjc.1997.427
   PubMed Web of Science ®Google Scholar
• Van Muijen GN, Cornelissen LM, Jansen CF, Figdor CG, Johnson JP, Brocker EB, Ruiter DJ. Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin Exp Metastasis 1991; 9:259-72; PMID:2060184; http://dx.doi.org/10.1007/BF01753729
   PubMed Web of Science ®Google Scholar
• Westphal JR, Van't Hullenaar R, Peek R, Willems RW, Crickard K, Crickard U, Askaa J, Clemmensen I, Ruiter DJ, De Waal RM. Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo. Int J Cancer 2000; 86:768-76; PMID:10842189; http://dx.doi.org/10.1002/(SICI)1097-0215(20000615)86:6%3c768::AID-IJC3%3e3.0.CO;2-E
   PubMed Web of Science ®Google Scholar
• Ezhilarasan R, Mohanam I, Govindarajan K, Mohanam S. Glioma cells suppress hypoxia-induced endothelial cell apoptosis and promote the angiogenic process. Int J Oncol 2007; 30:701-7; PMID:17273772; http://dx.doi.org/10.3892/ijo.30.3.701
   PubMed Web of Science ®Google Scholar
• Lazar-Molnar E, Hegyesi H, Toth S, Falus A. Autocrine and paracrine regulation by cytokines and growth factors in melanoma. Cytokine 2000; 12:547-54; PMID:10843728; http://dx.doi.org/10.1006/cyto.1999.0614
   PubMed Web of Science ®Google Scholar
• Streit M, Detmar M. Angiogenesis, lymphangiogenesis, and melanoma metastasis. Oncogene 2003; 22:3172-9; PMID:12789293; http://dx.doi.org/10.1038/sj.onc.1206457
   PubMed Web of Science ®Google Scholar
• Potgens AJ, Westphal HR, de Waal RM, Ruiter DJ. The role of vascular permeability factor and basic fibroblast growth factor in tumor angiogenesis. Biol Chem Hoppe Seyler 1995; 376:57-70; PMID:7540844
   PubMed Web of Science ®Google Scholar
• Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, Clark L, Bayani N, Coppe JP, Tong F et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 2006; 10:515-27; PMID:17157791; http://dx.doi.org/10.1016/j.ccr.2006.10.008
   PubMed Web of Science ®Google Scholar
• Deer EL, Gonzalez-Hernandez J, Coursen JD, Shea JE, Ngatia J, Scaife CL, Firpo MA, Mulvihill SJ. Phenotype and genotype of pancreatic cancer cell lines. Pancreas 2010; 39:425-35; PMID:20418756; http://dx.doi.org/10.1097/MPA.0b013e3181c15963
   PubMed Web of Science ®Google Scholar
• Shalini S, Dorstyn L, Dawar S, Kumar S. Old, new and emerging functions of caspases. Cell Death Differ 2015; 22:526-39; PMID:25526085; http://dx.doi.org/10.1038/cdd.2014.216
   PubMed Web of Science ®Google Scholar
• Wang Y, Becker D. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth. Nat Med 1997; 3:887-93; PMID:9256280; http://dx.doi.org/10.1038/nm0897-887
   PubMed Web of Science ®Google Scholar
• Graeven U, Rodeck U, Karpinski S, Jost M, Philippou S, Schmiegel W. Modulation of angiogenesis and tumorigenicity of human melanocytic cells by vascular endothelial growth factor and basic fibroblast growth factor. Cancer Res 2001; 61:7282-90; PMID:11585767
   PubMed Web of Science ®Google Scholar
• Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest 1999; 103:159-65; PMID:9916127; http://dx.doi.org/10.1172/JCI5028
   PubMed Web of Science ®Google Scholar
• Benjamin LE, Keshet E. Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A 1997; 94:8761-6; PMID:9238051; http://dx.doi.org/10.1073/pnas.94.16.8761
   PubMed Web of Science ®Google Scholar
• Munoz-Chapuli R, Quesada AR, Angel Medina M. Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci 2004; 61:2224-43; PMID:15338053; http://dx.doi.org/10.1007/s00018-004-4070-7
   PubMed Web of Science ®Google Scholar
• Anfuso CD, Giurdanella G, Motta C, Muriana S, Lupo G, Ragusa N, Alberghina M. PKCalpha-MAPK/ERK-phospholipase A2 signaling is required for human melanoma-enhanced brain endothelial cell proliferation and motility. Microvasc Res 2009; 78:338-57; PMID:19747926; http://dx.doi.org/10.1016/j.mvr.2009.09.001
   PubMed Web of Science ®Google Scholar
• Liu W, Davis DW, Ramirez K, McConkey DJ, Ellis LM. Endothelial cell apoptosis is inhibited by a soluble factor secreted by human colon cancer cells. Int J Cancer 2001; 92:26-30; PMID:11279602; http://dx.doi.org/10.1002/1097-0215(200102)9999:9999%3c::AID-IJC1151%3e3.0.CO;2-T
   PubMed Web of Science ®Google Scholar
• Sviderskaya EV, Gray-Schopfer VC, Hill SP, Smit NP, Evans-Whipp TJ, Bond J, Hill L, Bataille V, Peters G, Kipling D et al. p16/cyclin-dependent kinase inhibitor 2A deficiency in human melanocyte senescence, apoptosis, and immortalization: possible implications for melanoma progression. J Natl Cancer Inst 2003; 95:723-32; PMID:12759390; http://dx.doi.org/10.1093/jnci/95.10.723
   PubMedGoogle Scholar
• Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52:2745-56; PMID:4355998; http://dx.doi.org/10.1172/JCI107470
   PubMed Web of Science ®Google Scholar
• Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Pescatori M, Stubbs AP, van Ijcken WF, Dahlke MH, Eggenhofer E, Weimar W et al. Inflammatory conditions affect gene expression and function of human adipose tissue-derived mesenchymal stem cells. Clin Exp Immunol 2010; 162:474-86; PMID:20846162; http://dx.doi.org/10.1111/j.1365-2249.2010.04256.x
   PubMed Web of Science ®Google Scholar